Brokerages expect West Pharmaceutical Services Inc. (NYSE:WST) to report $416.20 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for West Pharmaceutical Services’ earnings, with estimates ranging from $411.50 million to $420.00 million. West Pharmaceutical Services posted sales of $382.30 million during the same quarter last year, which suggests a positive year-over-year growth rate of 8.9%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Thursday, February 15th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full year sales of $416.20 million for the current year. For the next fiscal year, analysts forecast that the business will report sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow West Pharmaceutical Services.
WST has been the topic of several recent research reports. Zacks Investment Research downgraded West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Goldman Sachs Group initiated coverage on West Pharmaceutical Services in a report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 price target on the stock. Bank of America downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target on the stock. in a report on Tuesday, October 17th. Finally, Wells Fargo & Co raised their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $108.17.
West Pharmaceutical Services (WST) traded up $0.71 during trading hours on Friday, reaching $91.96. The company’s stock had a trading volume of 635,869 shares, compared to its average volume of 351,009. The company has a current ratio of 2.59, a quick ratio of 1.87 and a debt-to-equity ratio of 0.15. West Pharmaceutical Services has a 52 week low of $77.97 and a 52 week high of $103.36. The company has a market cap of $6,775.58, a P/E ratio of 39.33, a PEG ratio of 1.94 and a beta of 1.04.
The business also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Thursday, January 18th were issued a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. The ex-dividend date was Wednesday, January 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.31%.
In related news, CFO William J. Federici sold 21,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $99.01, for a total value of $2,079,210.00. Following the sale, the chief financial officer now owns 190,493 shares of the company’s stock, valued at approximately $18,860,711.93. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in WST. Citigroup Inc. raised its stake in West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares in the last quarter. Nomura Holdings Inc. bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at $201,000. Grandfield & Dodd LLC bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at $201,000. Private Advisor Group LLC bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at $202,000. Finally, Alps Advisors Inc. bought a new stake in West Pharmaceutical Services during the 4th quarter valued at $206,000. 92.44% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate West Pharmaceutical Services Inc. (WST) Will Post Quarterly Sales of $416.20 Million” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/12/brokerages-anticipate-west-pharmaceutical-services-inc-wst-will-post-quarterly-sales-of-416-20-million.html.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.